Price Alert

Tarsus Pharmaceuticals In... (TARS)

NASDAQ: TARS · Real-Time Price · USD

57.41

-0.02 (-0.03%)

At close: Sep 05, 2025, 9:35 AM

Tarsus Pharmaceuticals Statistics

Share Statistics

Tarsus Pharmaceuticals has 42.21M shares outstanding. The number of shares has increased by 10.44% in one year.

Shares Outstanding	42.21M
Shares Change (YoY)	10.44%
Shares Change (QoQ)	0.98%
Owned by Institutions (%)	99.99%
Shares Floating	38.56M
Failed to Deliver (FTD) Shares	1,900
FTD / Avg. Volume	0.3%

Short Selling Information

The latest short interest is 7.34M, so 17.39% of the outstanding shares have been sold short.

Short Interest	7.34M
Short % of Shares Out	17.39%
Short % of Float	17.98%
Short Ratio (days to cover)	9.14

Valuation Ratios

The PE ratio is -18.02 and the forward PE ratio is 59.51. Tarsus Pharmaceuticals's PEG ratio is 0.54.

PE Ratio	-18.02
Forward PE	59.51
PS Ratio	11.38
Forward PS	4
PB Ratio	9.27
P/FCF Ratio	-24.61
PEG Ratio	0.54

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Tarsus Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.42, with a Debt / Equity ratio of 0.32.

Current Ratio	4.42
Quick Ratio	4.39
Debt / Equity	0.32
Debt / EBITDA	-0.68
Debt / FCF	-0.86
Interest Coverage	-15.36

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$566.42K
Profits Per Employee	$-357.75K
Employee Count	323
Asset Turnover	0.49
Inventory Turnover	4.9

Taxes

Income Tax	n/a
Effective Tax Rate	0%

Stock Price Statistics

The stock price has increased by 110.29% in the last 52 weeks. The beta is 0.79, so Tarsus Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.79
52-Week Price Change	110.29%
50-Day Moving Average	46.58
200-Day Moving Average	47.76
Relative Strength Index (RSI)	69.41
Average Volume (20 Days)	634,895

Income Statement

In the last 12 months, Tarsus Pharmaceuticals had revenue of 182.95M and earned -115.55M in profits. Earnings per share was -3.07.

Revenue	182.95M
Gross Profit	170.13M
Operating Income	-120.57M
Net Income	-115.55M
EBITDA	-106.48M
EBIT	-108.11M
Earnings Per Share (EPS)	-3.07

Full Income Statement

Balance Sheet

The company has 94.82M in cash and 72.45M in debt, giving a net cash position of 22.37M.

Cash & Cash Equivalents	94.82M
Total Debt	72.45M
Net Cash	22.37M
Retained Earnings	-360.21M
Total Assets	494.99M
Working Capital	384.18M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -83.03M and capital expenditures -1.57M, giving a free cash flow of -84.59M.

Operating Cash Flow	-83.03M
Capital Expenditures	-1.57M
Free Cash Flow	-84.59M
FCF Per Share	-2.25

Full Cash Flow Statement

Margins

Gross margin is 92.99%, with operating and profit margins of -65.9% and -63.16%.

Gross Margin	92.99%
Operating Margin	-65.9%
Pretax Margin	-63.16%
Profit Margin	-63.16%
EBITDA Margin	-58.2%
EBIT Margin	-65.9%
FCF Margin	-46.24%

Dividends & Yields

TARS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for TARS is $66, which is 14.9% higher than the current price. The consensus rating is "Buy".

Price Target	$66
Price Target Difference	14.9%
Analyst Consensus	Buy
Analyst Count	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	8.32
Piotroski F-Score	3